Figure 2.
Proposed workflow for non-tuberculous mycobacteria (NTM) drug discovery. Activities and assays from whole-cell library screening to the preclinical development compound are shown. Light blue boxes indicate NTM-specific assays discussed in more detail in the text. Assay and model gaps are in bold. Gray box indicates generic drug discovery activities and assays described elsewhere [148,149]. Abbreviations: PK, pharmacokinetics; tox, cytotoxicity assays.